Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Atheroembolic Renal Disease.

Joseph A. Vassalotti1, Fernando A. Delgado, Andrew Whelton

  • 1Division of Nephrology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

American Journal of Therapeutics
|July 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomized double-blind pilot study of universal, species abundant, multiallergen subcutaneous immunotherapy for moderate-severe allergic rhinitis.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2023
Same author

Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial.

Arthritis & rheumatology (Hoboken, N.J.)·2022
Same author

Long-Term Mortality and Bone Safety in Patients with End-Stage Renal Disease Receiving Lanthanum Carbonate.

Nephron·2018
Same author

Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study.

Arthritis & rheumatology (Hoboken, N.J.)·2018
Same author

Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study.

Arthritis research & therapy·2018
Same author

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.

The New England journal of medicine·2018
Same journal

Abrocitinib as a Novel Therapeutic Option for Elastolytic Giant Cell Granuloma: A Case Report.

American journal of therapeutics·2026
Same journal

Dupilumab for Lichen Amyloidosis in an Elderly Multimorbid Patient.

American journal of therapeutics·2026
Same journal

Deucravacitinib for Generalized Pustular Psoriasis and Comorbid Polymyositis: Dual Efficacy and Favorable Safety.

American journal of therapeutics·2026
Same journal

Repurposed Drugs and Cardiovascular Morbidity: A Cost-Effectiveness Analysis.

American journal of therapeutics·2026
Same journal

Do Not Treat a Sequencing Report: Therapeutic Stewardship in Endometrial Microbiome Testing.

American journal of therapeutics·2026
Same journal

Right Side Accessory Pathway Mediated Cardiomyopathy Treated with Amiodarone: First Adult Case Report.

American journal of therapeutics·2026
See all related articles

Cholesterol emboli increasingly cause kidney dysfunction in older adults, leading to acute renal failure. Diagnosis involves clinical findings and sometimes biopsy, with supportive care focusing on blood pressure and cholesterol management.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Pathology

Background:

  • Cholesterol emboli are an emerging cause of renal dysfunction, particularly in the aging US population.
  • These atheroemboli obstruct small renal vessels, causing ischemia and a vasculitis-like inflammatory response.
  • The condition can be triggered by vascular procedures or medications, or occur spontaneously.

Purpose of the Study:

  • To highlight the increasing recognition of cholesterol emboli as a cause of renal dysfunction.
  • To outline the clinical presentation, diagnostic approaches, and management strategies for cholesterol emboli.
  • To differentiate cholesterol emboli from other causes of acute renal failure.

Main Methods:

  • Review of clinical presentations, diagnostic findings, and therapeutic approaches for cholesterol emboli.

Related Experiment Videos

  • Emphasis on physical examination findings (e.g., livedo reticularis, extrarenal emboli) and laboratory results (e.g., eosinophilia, elevated ESR).
  • Discussion of diagnostic confirmation via biopsy (kidney, skin, muscle) when clinical diagnosis is uncertain.

    • Main Results:

    • Cholesterol emboli present a spectrum of acute renal failure, from asymptomatic to life-threatening.
    • Physical findings like livedo reticularis and laboratory results such as eosinophilia can be suggestive.
    • Kidney involvement is frequent, often presenting with partial obstruction and ischemia.

    Conclusions:

    • Cholesterol emboli are a significant cause of kidney injury in the elderly, mimicking other conditions like vasculitis.
    • Diagnosis can be clinical, supported by characteristic physical and laboratory findings, or confirmed by biopsy.
    • Supportive therapy, including hypertension and hypercholesterolemia management, is crucial.